S&P 500
7,615.40
-0.09%
Dow Jones
51,327.00
-0.09%
Nasdaq 100
30,644.80
-0.23%
Russell 2000
2,928.08
-0.17%
FTSE 100
10,381.30
-0.06%
Nikkei 225
68,144.20
+0.95%

Investing

Critical Therapeutics (CRTX): What Goes Up…

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published

Critical Therapeutics (CRTX) is having a hell of a run today. The stock is up 31% to $3.50 on almost 11.8 million shares. At one point, the share hit $4.10.

The reason? The Food and Drug Administration approved its chronic asthma drug. Cowen & Co."predicted the franchise will bring the company $125 million in revenue in 2011." The product is marketed with Merck KGaA.

The stock increase brings the CRTX market cap to $150 million.

In the last quarter, the company had revenue of $3.5 million and an operating loss of $5.2 million. The company has about $45 million in cash.

Is the stock worth the much higher price. Perhaps. But, the company is small and investors might like to see it bought at this price. Takes away what appear to be a huge risk.

Douglas A. McIntyre

Follow 24/7 Wall St. on Google
Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

Critical Therapeutics Inc (CRTX): Too High, Too Fast?

Share in Shares of Critical Therapeutics (CRTX) Inc are up 40% to after "the drug developer received Food and Drug…

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure
Jon C. Ogg |

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and…

Meme Stock Movers for 10/27: Canaan, Cortexyme, Farmmi, Robinhood
Paul Ausick |

Meme Stock Movers for 10/27: Canaan, Cortexyme, Farmmi, Robinhood

A big miss on revenue estimates is hammering shares of one stock that meme stock investors love to hate.

Lee Jackson |

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

ThinkstockWith the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back…

Breast Cancer Drug Can Bring Exponential Sales Growth for Puma Biotechnology
Jon C. Ogg |

Breast Cancer Drug Can Bring Exponential Sales Growth for Puma Biotechnology

The world of biotech can be a rags-to-riches story for companies that build up a drug candidate and secure FDA…

Valuation and Dividend Safety Analysis: Pfizer (PFE)
247patrick |

Valuation and Dividend Safety Analysis: Pfizer (PFE)

Here is a valuation and dividend safety analysis of Pfizer stock.

Paul Ausick |

Merck Earnings Fail to Dazzle, but the Company’s Story Remains Strong

Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to…

Chris Lange |

Why the DepoMed Drop Is a Gross Overreaction

ThinkstockSometimes, or lots of times, investors and markets take things a little too far. For instance, a stock might overreact,…

PPD Proves Optimistic in IPO Debut
Chris Lange |

PPD Proves Optimistic in IPO Debut

PPD made an exciting entrance to the market Thursday, pricing its shares at the high end of the expected price…

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 153,197,465
Enphase Energy
ENPH • Vol: 8,360,053
Corning
GLW • Vol: 18,152,646
Alexandria Real Estate Equities
ARE • Vol: 4,337,015
Aptiv
APTV • Vol: 6,761,325

Top Losing Stocks

Trade Desk
TTD • Vol: 21,905,513
Intuit
INTU • Vol: 7,383,018
Coterra Energy
CTRA • Vol: 73,319,495
Cboe Global Markets
CBOE • Vol: 5,000,011
HP
HPQ • Vol: 29,259,826